Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial

Respiratory Research

Table 4 Time to first exacerbation and first hospitalised exacerbation according to post-bronchodilator FEV₁ RoD quartiles.

	Tiotropium	Control	Hazard ratio(tiotropium versus control)*(95% CI)
Time to first exacerbation, median month
Q1	19.4	14.6	0.80 (0.70 to 0.92)
Q2	22.4	13.6	0.83 (0.73 to 0.94)
Q3	16.6	16.3	0.97 (0.86 to 1.11)
Q4	14.9	12.7	0.88 (0.78 to 1.01)
Time to first exacerbation leading to hospitalization (first quartile), month
Q1	NA	39.9	0.72 (0.57 to 0.91)
Q2	47.2	32.5	0.73 (0.59 to 0.90)
Q3	37.0	40.2	1.05 (0.86 to 1.30)
Q4	28.5	26.0	0.98 (0.81 to 1.18)

*Hazard ratio based on Cox regression with treatment, rate of decline quartile, and rate of decline by treatment interaction as covariates.
Abbreviations: FEV₁, forced expiratory volume in 1 second; RoD, rate of decline; CI, confidence interval.

ISSN: 1465-993X